Australia's Healius up; Macquarie trims PT, earnings view

Healius

22/02/2024 03:23

** Analysts at Macquarie reduce price target on Healius
 HLS.AX  to A$1.40 from A$1.50, maintain "neutral" rating
    ** However, the new PT remains slightly above the median PT
of A$1.30 from 12 analysts - LSEG data
    ** Shares of the pathology and imaging services provider are
up 3.2% at A$1.363, following a 5.7% decline in the previous
session
    ** Macquarie cuts EPS estimates for FY24, FY25, and FY26 by
50%, 16% and 9% respectively, reflecting revised operational
assumptions
    ** Downgrades FY24 EBIT forecast to A$70 mln ($45.85 mln)
from A$80 mln - bottom end of co's expected range of A$70 mln to
A$80 mln
    ** Eight of 12 analysts rate the stock "hold" and four
"sell" or lower - LSEG

($1 = 1.5267 Australian dollars)

 (Reporting by Sneha Kumar in Bengaluru)
 ((Sneha.Kumar@thomsonreuters.com;))